Blood: Progenion of large B-cell lymphoma (PMBCL) treated with R-CHOP

the combination of the !----, litoxiin, increases the cure rate for primary isolation of large B-cell lymphoma (PMBCL)but the type of major therapy and the role of radiotherapy (RT) are still uncleartherefore, this study is intended to assess the prognosis of PMBCL patients primarily treated with R-CHOP, and FDG-PET scans at end of treatment to guide the effects of consolidation RTrecruit pmBCL patients over the age of 18 who were treated with R-chemotherapyUntil 2005, patients were primarily advised to use R-CHOP and RT therapy (RT age)since 2005, EOT PET has been used to guide RT, and only PET-positive patients receive RT treatment (PET age)screened 159 patients, 94% of whom were treated with R-CHOP and 44% received RT therapy (in the RT era, 78% received RT treatment; in the PET era, 28% received RT treatment)the five-year progress time (TTP) and overall survival rate (OS) of the entire queue were 80% and 89%, respectively, similar throughout the treatment periodoverall, 10% of patients are treated with refracted diseases113 patients underwent EOT PET scans: 63% negative and 37% positive5-year TTP in patients with eOT PET scans negative and positive was 90% vs 71%, and 5 years OS was 97% vs 88%for patients who received a Deauville (D) rated PET scan (103), the five-year TTP for negative patients (D1-D3, DX) was 91%, and the prognosis of D5 was significantly worse than D4 '5 tTP: 33% vs 87%, p.0002)in summary, the prognosis of PMBCL patients treated with R-CHOP is better, and the pet adaptive method can prevent most patients from receiving unnecessary RT treatmenta small number of patients who are difficult to treat or benefit from alternative therapies